TCN 213CAS# 556803-08-8 |
- Nadifloxacin
Catalog No.:BCC4804
CAS No.:124858-35-1
- Calcipotriol monohydrate
Catalog No.:BCC1445
CAS No.:147657-22-5
- Halobetasol Propionate
Catalog No.:BCC4664
CAS No.:66852-54-8
- Dihydroartemisinin
Catalog No.:BCN6264
CAS No.:71939-50-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 556803-08-8 | SDF | Download SDF |
PubChem ID | 2608149 | Appearance | Powder |
Formula | C18H24N4OS2 | M.Wt | 376.54 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 75 mM in DMSO and to 10 mM in ethanol | ||
Chemical Name | 2-[[5-(benzylamino)-1,3,4-thiadiazol-2-yl]sulfanyl]-N-(cyclohexylmethyl)acetamide | ||
SMILES | C1CCC(CC1)CNC(=O)CSC2=NN=C(S2)NCC3=CC=CC=C3 | ||
Standard InChIKey | XBAZPYFIYYCZBO-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H24N4OS2/c23-16(19-11-14-7-3-1-4-8-14)13-24-18-22-21-17(25-18)20-12-15-9-5-2-6-10-15/h2,5-6,9-10,14H,1,3-4,7-8,11-13H2,(H,19,23)(H,20,21) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | NMDA receptor antagonist, selective for GluN1/GluN2A (formally NR1/NR2A) (pIC50 = 5.4) over GluN1/GluN2B (formally NR1/NR2B) containing receptors. |
TCN 213 Dilution Calculator
TCN 213 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6558 mL | 13.2788 mL | 26.5576 mL | 53.1152 mL | 66.394 mL |
5 mM | 0.5312 mL | 2.6558 mL | 5.3115 mL | 10.623 mL | 13.2788 mL |
10 mM | 0.2656 mL | 1.3279 mL | 2.6558 mL | 5.3115 mL | 6.6394 mL |
50 mM | 0.0531 mL | 0.2656 mL | 0.5312 mL | 1.0623 mL | 1.3279 mL |
100 mM | 0.0266 mL | 0.1328 mL | 0.2656 mL | 0.5312 mL | 0.6639 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Boc-D-Thr-OH
Catalog No.:BCC3453
CAS No.:55674-67-4
- Deltonin
Catalog No.:BCC8933
CAS No.:55659-75-1
- Syneilesine
Catalog No.:BCN2144
CAS No.:55652-65-8
- Cepharadione B
Catalog No.:BCN6524
CAS No.:55610-02-1
- Cepharadione A
Catalog No.:BCN3950
CAS No.:55610-01-0
- Aristololactam II
Catalog No.:BCN8095
CAS No.:55610-00-9
- 1-Oxo-4-hydroxy-2-en-4-ethylcyclohexa-5,8-olide
Catalog No.:BCN1417
CAS No.:55604-88-1
- Alverine Citrate
Catalog No.:BCC4619
CAS No.:5560-59-8
- Alliin
Catalog No.:BCN3869
CAS No.:556-27-4
- H-D-Tyr-OH
Catalog No.:BCC3134
CAS No.:556-02-5
- Acesulfame Potassium
Catalog No.:BCC4755
CAS No.:55589-62-3
- Agrimol B
Catalog No.:BCN5017
CAS No.:55576-66-4
- 1-Octacosanol
Catalog No.:BCN2973
CAS No.:557-61-9
- (24S)-24,25-Dihydroxyvitamin D3
Catalog No.:BCC1290
CAS No.:55700-58-8
- Secalciferol
Catalog No.:BCC1942
CAS No.:55721-11-4
- Salinomycin sodium salt
Catalog No.:BCC1917
CAS No.:55721-31-8
- Boc-D-Ile-OH
Catalog No.:BCC3407
CAS No.:55721-65-8
- Stigmasta-4,22-dien-3-one
Catalog No.:BCN5745
CAS No.:55722-32-2
- 3-Deoxo-1Beta-methoxyjioglutolide
Catalog No.:BCN7034
CAS No.:55732-36-0
- Oxoglaucine
Catalog No.:BCN2650
CAS No.:5574-24-3
- Litorin
Catalog No.:BCC5846
CAS No.:55749-97-8
- Crocin II
Catalog No.:BCN1027
CAS No.:55750-84-0
- WZ811
Catalog No.:BCC4448
CAS No.:55778-02-4
- Sunitinib
Catalog No.:BCC4064
CAS No.:557795-19-4
Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist.[Pubmed:22022974]
Br J Pharmacol. 2012 Jun;166(3):924-37.
BACKGROUND AND PURPOSE: Developmental switches in NMDA receptor subunit expression have been inferred from studies of GluN2 expression levels, changes in kinetics of glutamatergic synaptic currents and sensitivity of NMDA receptor-mediated currents to selective GluN2B antagonists. Here we use TCN 213, a novel GluN2A-selective antagonist to identify the presence of this subunit in functional NMDA receptors in developing cortical neurones. EXPERIMENTAL APPROACH: Two-electrode voltage-clamp (TEVC) recordings were made from Xenopus laevis oocytes to determine the pharmacological activity of TCN 213 at recombinant NMDA receptors. TCN 213 antagonism was studied in cultures of primary cortical neurones, assessing the NMDA receptor dependency of NMDA-induced excitotoxicity and monitoring developmental switches in NMDA receptor subunit composition. KEY RESULTS: TCN 213 antagonism of GluN1/GluN2A NMDA receptors was dependent on glycine but independent of glutamate concentrations in external recording solutions. Antagonism by TCN 213 was surmountable and gave a Schild plot with unity slope. TCN 213 block of GluN1/GluN2B NMDA receptor-mediated currents was negligible. In cortical neurones, at a early developmental stage predominantly expressing GluN2B-containing NMDA receptors, TCN 213 failed to antagonize NMDA receptor-mediated currents or to prevent GluN2B-dependent, NMDA-induced excitoxicity. In older cultures (DIV 14) or in neurones transfected with GluN2A subunits, TCN 213 antagonized NMDA-evoked currents. Block by TCN 213 of NMDA currents inversely correlated with block by ifenprodil, a selective GluN2B antagonist. CONCLUSIONS AND IMPLICATIONS: TCN 213 selectively blocked GluN1/GluN2A over GluN1/GluN2B NMDA receptors allowing direct dissection of functional NMDA receptors and pharmacological profiling of developmental changes in native NMDA receptor subunit composition.
Sensitivity of N-methyl-D-aspartate receptor-mediated excitatory postsynaptic potentials and synaptic plasticity to TCN 201 and TCN 213 in rat hippocampal slices.[Pubmed:25413830]
J Pharmacol Exp Ther. 2015 Feb;352(2):267-73.
Whereas ifenprodil has been used as a selective GluN1/GluN2B (NR1/NR2B, B-type) receptor antagonist to distinguish between GluN2B (NR2B) and GluN2A (NR2A)-containing N-methyl-d-aspartate receptors (NMDARs), TCN 201 (3-chloro-4-fluoro-N-[4-[[2-(phenylcarbonyl)hydrazino]carbonyl]benzyl]benzenesulp honamide) and TCN 213 [N-(cyclohexylmethyl)-2-[{5-[(phenylmethyl)amino]-1,3,4-thiadiazol-2-yl}thio]acet amide] have been found to be selective GluN1/GluN2A (NR1/NR2A, A-type) antagonists. Based on the premise that A- and B-types are major synaptic NMDARs, we examined whether inhibition of NMDAR excitatory postsynaptic potentials (EPSPs) by the TCN compounds and ifenprodil are complementary. Contrary to this prediction, inhibition of NMDAR EPSPs by the TCN compounds and ifenprodil were largely overlapping in the CA1 region of hippocampal slices from 30-day-old rats. After partial inhibition by ifenprodil, TCN compounds produced little further suppression of NMDAR EPSPs. Similarly, after partial inhibition by TCN compounds ifenprodil failed to further suppress NMDAR EPSPs. However, low micromolar d-2-amino-5-phosphonovalerate, a competitive NMDAR antagonist, which alone only partially inhibits NMDAR EPSPs, markedly suppresses residual NMDAR responses in the presence of ifenprodil or the TCNs, suggesting that low 2-amino-5-phosphonovalerate antagonizes both ifenprodil- and TCN-insensitive synaptic NMDARs. These observations can be most readily interpreted if ifenprodil and TCNs act on a similar population of synaptic NMDARs. Recent lines of evidence suggest that the majority of hippocampal synaptic NMDARs are triheteromers. If so, modulation of GluN2A, and not just GluN2B NMDARs, could dampen long-term depression (LTD). Indeed, both TCNs, like ifenprodil, blocked LTD, suggesting the involvement of ifenprodil- and TCN-sensitive NMDARs in LTD induction. However, the TCNs plus ifenprodil failed to inhibit long-term potentiation (LTP), suggesting that neither ifenprodil- nor TCN-sensitive NMDARs are essential for LTP induction.
Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors.[Pubmed:20810618]
J Pharmacol Exp Ther. 2010 Dec;335(3):636-44.
NR1/NR2A is a subtype of N-methyl-d-aspartate receptors (NMDARs), which are glutamate and glycine-gated Ca(2+)-permeable channels highly expressed in the central nervous system. A high-throughput screening (HTS) campaign using human osteosarcoma (U-2 OS) cells transiently transduced with NR1/NR2A NMDAR subunits, tested in a specifically designed fluorometric imaging plate reader (FLIPR)/Ca(2+) assay, identified sulfonamide derivative series, exemplified by 3-chloro-4-fluoro-N-[(4-{[2-(phenylcarbonyl)hydrazino]carbonyl}phenyl)methyl]benz enesulfonamide (compound 1) and thiodiazole derivative N-(cyclohexylmethyl)-2-({5-[(phenylmethyl)amino]-1,3,4-thiadiazol-2-yl}thio)aceta mide (compound 13) as novel NR1/NR2A receptor antagonists. Compounds 1 and 13 displayed submicromolar and micromolar potency at NR1/NR2A receptor, respectively, although they did not show activity at NR2B-containing receptor up to 50 muM concentration. Addition of 1 mM glycine, but not 1 mM l-glutamate, was able to surmount compound 1 and 13 inhibitory effects in FLIPR NR1/NR2A assay. However, compounds 1 and 13 displaced a glutamate site antagonist [(3)H]d,l-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid ([(3)H]CGP 39653) to a greater extent than the glycine site antagonist [(3)H]3-[(E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-1H-indole-2-carboxylic acid ([(3)H]MDL 105,519), in rat brain cortex binding assay. Results of FLIPR cell-based, electrophysiological, and biochemical binding assays suggest that compounds 1 and 13 are the prototypes of novel classes of NMDAR ligands, which to the best of our knowledge are the first selective antagonists at NR1/NR2A over NR1/NR2B receptor, and might constitute useful tools able to elucidate the relative role of the NR2A subunit in physiological and pathological conditions.